ArticleBrain communications2020
Longitudinal evaluation of the natural history of amyloid-β in plasma and brain.
Article in Brain communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 30 citations in OpenAlex.
- Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study.Brain : a journal of neurology · 2023Trial
- Longitudinal trajectories of neurodegenerative biomarkers in the blood of patients with chronic heart failure.ESC heart failure · 2026Article
- Nano-based spectroscopic approaches for early diagnosis of Alzheimer's disease: critical insights into amyloid-β and tau biomarker biology and detection tools.Biophysical reviews · 2026Review
- Weekly fluctuations of plasma amyloid-beta in Alzheimer's disease: implications for biomarker reliability.Alzheimer's research & therapy · 2026Article
- Plasma Aβ42/40 predicts progression from Aβ-amyloid negative to positive PET scans.The journal of prevention of Alzheimer's disease · 2026Article
- Streamlined resource-efficient plasma amyloid-beta mass spectrometry assay has improved biomarker performance in preclinical Alzheimer's disease.Nature communications · 2026Article
- Evaluation of a panel of plasma biomarkers for Alzheimer's disease in a diverse research cohort.Journal of Alzheimer's disease : JAD · 2026Article
- The amyloid beta 42/38 ratio as a plasma biomarker of early memory deficits in cognitively unimpaired older adults.Neurobiology of aging · 2024Article
- Diffusion MRI relates to plasma Aβ42/40 in PET negative participants without dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Midlife cumulative deficit frailty predicts Alzheimer's disease-related plasma biomarkers in older adults.Age and ageing · 2024Article
- New precision medicine avenues to the prevention of Alzheimer's disease from insights into the structure and function of γ-secretases.The EMBO journal · 2024Review
- Alcohol Use Disorder and Dementia: A Review.Alcohol research : current reviews · 2024Review
- Longitudinal changes in Alzheimer's-related plasma biomarkers and brain amyloid.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Article
- Annual stability of the plasma Aß40/42 ratio and associated factors.Annals of clinical and translational neurology · 2023Article
- Plasma Aβ42/Aβ40 Ratios in Older People With Human Immunodeficiency Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Prospective analysis of plasma amyloid beta and postoperative delirium in the Interventions for Postoperative Delirium: Biomarker-3 study.British journal of anaesthesia · 2023Article
- Longitudinal changes in Alzheimer's-related plasma biomarkers and brain amyloid.medRxiv : the preprint server for health sciences · 2023Article
- Clinical Evaluation of Cerebrospinal Fluid p217tau and Neurofilament Light Chain Levels in Patients with Alzheimer's Disease or Other Neurological Diseases.Journal of Alzheimer's disease : JAD · 2023Article
- Contribution of clinical information to the predictive performance of plasma β-amyloid levels for amyloid positron emission tomography positivity.Frontiers in aging neuroscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasma amyloid-β peptide concentration has recently been shown to have high accuracy to predict amyloid-β plaque burden in the brain. These amyloid-β plasma markers will allow wider screening of the population and simplify and reduce screening costs for therapeutic trials in Alzheimer's disease. The aim of this study was to determine how longitudinal changes in blood amyloid-β track with changes in brain amyloid-β. Australian Imaging, Biomarker and Lifestyle study participants with a minimum of two assessments were evaluated (111 cognitively normal, 7 mild cognitively impaired, 15 participants with Alzheimer's disease). Amyloid-β burden in the brain was evaluated through PET and was expressed in Centiloids. Total protein amyloid-β 42/40 plasma ratios were determined using ABtest
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.